{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T11:26:51Z","timestamp":1793014011381,"version":"4.5.0"},"reference-count":147,"publisher":"Oxford University Press (OUP)","issue":"40","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>During the 1960s, in a pioneering way, plasmapheresis was used to treat children with homozygous familial hypercholesterolaemia (HoFH). Over the years, apheresis has evolved to increasingly selective methods, which have been used in paediatric HoFH since the 1990s. Today, lipoprotein apheresis (LA) is able to selectively remove atherogenic apoB100\u2013containing lipoproteins from the blood: the main component of LDL-cholesterol, VLDL-cholesterol, and lipoprotein(a). Lipoprotein apheresis has demonstrated protective effects in the endothelium and microcirculation, prevention of the development of new aortic and coronary lesions in HoFH, reducing the incidence of major cardiovascular events, and proving helpful in subjects who fail to reach the LDL-cholesterol target or who have elevated lipoprotein(a) levels in secondary prevention. Although advances in pharmacological therapies (proprotein convertase subtilisin\/kexin Type 9 inhibitors, antisense oligonucleotides, and siRNA-based treatments) have expanded the options for lipid management, LA remains a safe therapeutic approach for patients with severe lipid disorders, including HoFH, to reduce their cardiovascular risks. Currently, to put LA into perspective, some obstacles need to be overcome, including (i) the underdiagnosis of HoFH and high lipoprotein(a) level; (ii) therapeutic inertia resulting from the use of new lipid-lowering drugs with partial achievement of lipid targets; and (iii) availability of qualified LA centres and practitioners. Further prospective studies may prove useful to identify other therapeutic scenarios for LA, such as renal disease, diabetic foot ulcer, peripheral arterial disease, pre-eclampsia, macular degeneration, or sudden sensorineural hearing loss. In these clinical settings, prospective, randomized clinical trials are therefore warranted.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehag328","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T11:43:41Z","timestamp":1776253421000},"page":"5959-5978","source":"Crossref","is-referenced-by-count":4,"title":["Lipoprotein apheresis in the era of new lipid-lowering therapies"],"prefix":"10.1093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4607-0373","authenticated-orcid":false,"given":"Francesco","family":"Sbrana","sequence":"first","affiliation":[{"name":"Lipoapheresis Unit\u2014Reference Center for Diagnosis and Treatment of Inherited Dyslipidemias, Fondazione Toscana \u2018Gabriele Monasterio\u2019 , Via Moruzzi, 1, Pisa 56124 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Dal Pino","sequence":"additional","affiliation":[{"name":"Lipoapheresis Unit\u2014Reference Center for Diagnosis and Treatment of Inherited Dyslipidemias, Fondazione Toscana \u2018Gabriele Monasterio\u2019 , Via Moruzzi, 1, Pisa 56124 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker J J","family":"Schettler","sequence":"additional","affiliation":[{"name":"Centre of Nephrology G\u00f6ttingen GbR , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Muso","sequence":"additional","affiliation":[{"name":"Department of Food and Nutrition, Faculty of Contemporary Life Studies, Kyoto Kacho University , Kyoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Harada-Shiba","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Osaka Medical and Pharmaceutical University , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Di Mola","sequence":"additional","affiliation":[{"name":"Dialysis and Apheresis Program, Department of Nephrology, The Hospital for Sick Children , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7180-5517","authenticated-orcid":false,"given":"Maki","family":"Kagitani","sequence":"additional","affiliation":[{"name":"Blood Purification Center, Osaka Medical and Pharmaceutical University , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Pineda","sequence":"additional","affiliation":[{"name":"Department of Food and Nutrition, Faculty of Contemporary Life Studies, Kyoto Kacho University , Kyoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Selke","sequence":"additional","affiliation":[{"name":"Rostock Division, akquinet Tech@Spree GmbH , Rostock ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Jenke","sequence":"additional","affiliation":[{"name":"Rostock Division, akquinet Tech@Spree GmbH , Rostock ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Zimmermann","sequence":"additional","affiliation":[{"name":"BioArtProducts GmbH (B.A.P.) , Rostock ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanja","family":"Bernhardt","sequence":"additional","affiliation":[{"name":"Center for Nephrology, Hypertension, and Metabolic Diseases , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Bigazzi","sequence":"additional","affiliation":[{"name":"Lipoapheresis Unit\u2014Reference Center for Diagnosis and Treatment of Inherited Dyslipidemias, Fondazione Toscana \u2018Gabriele Monasterio\u2019 , Via Moruzzi, 1, Pisa 56124 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Heigl","sequence":"additional","affiliation":[{"name":"Medical Care Center Kempten-Allg\u00e4u , Kempten ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Gr\u00fctzmacher","sequence":"additional","affiliation":[{"name":"AGAPLESION MVZ Markus Hospital , Frankfurt ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"L\u00f6hlein","sequence":"additional","affiliation":[{"name":"German Society of Lipidology e. V. (DGFL)\u2014Lipid League , Gelnhausen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Klingel","sequence":"additional","affiliation":[{"name":"Apheresis Research Institute , Cologne ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Corciulo","sequence":"additional","affiliation":[{"name":"Lipoapheresis Unit\u2014Reference Center for Diagnosis and Treatment of Inherited Dyslipidemias, Fondazione Toscana \u2018Gabriele Monasterio\u2019 , Via Moruzzi, 1, Pisa 56124 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Hohenstein","sequence":"additional","affiliation":[{"name":"1st Dept. Internal Medicine, University of Mainz ,","place":["Germany"]},{"name":"Nephrological Center Villingen-Schwenningen , Villingen-Schwenningen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfang","family":"Ramlow","sequence":"additional","affiliation":[{"name":"Apheresis Center Rostock (ACR) , Rostock ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Vogt","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik 4, Universit\u00e4t M\u00fcnchen , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Ramunni","sequence":"additional","affiliation":[{"name":"Department of Internal and Public Medicine, Division of Nephrology, University of Bari ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Emdin","sequence":"additional","affiliation":[{"name":"Lipoapheresis Unit\u2014Reference Center for Diagnosis and Treatment of Inherited Dyslipidemias, Fondazione Toscana \u2018Gabriele Monasterio\u2019 , Via Moruzzi, 1, Pisa 56124 ,","place":["Italy"]},{"name":"Health Science Interdisciplinary Center Scuola Superiore Sant'Anna , Pisa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Sampietro","sequence":"additional","affiliation":[{"name":"Lipoapheresis Unit\u2014Reference Center for Diagnosis and Treatment of Inherited Dyslipidemias, Fondazione Toscana \u2018Gabriele Monasterio\u2019 , Via Moruzzi, 1, Pisa 56124 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Julius","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital Carl Gustav Carus at the Technische Universit\u00e4t Dresden , Dresden ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schlieper","sequence":"additional","affiliation":[{"name":"Center for Nephrology, Hypertension, and Metabolic Diseases , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Stefanutti","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Extracorporeal Therapeutic Techniques Unit, Lipid Clinic and Atherosclerosis Prevention Centre, Regional Centre for Rare Diseases, Immunohematology and Transfusion Medicine, Umberto I Hospital, \u2018Sapienza\u2019 University of Rome , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M","family":"Moriarty","sequence":"additional","affiliation":[{"name":"Atherosclerosis and Lipid-Apheresis Center, University of Kansas Medical Center , Kansas City, KS, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"2026102519532179300_ehag328-B1","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.cardfail.2004.10.003","article-title":"Bloodletting as a cure for dropsy: heart failure down the ages","volume":"11","author":"Ventura","year":"2005","journal-title":"J Card Fail"},{"key":"2026102519532179300_ehag328-B2","first-page":"166","article-title":"Plasma removal with return of corpuscles (plasmapheresis)","volume":"11","author":"Abel","year":"1990","journal-title":"Trans Sci"},{"key":"2026102519532179300_ehag328-B3","first-page":"21","article-title":"Continuous flow membrane filtration of plasma from whole blood","volume":"24","author":"Solomon","year":"1978","journal-title":"Trans Am Soc Artif Intern Organs"},{"key":"2026102519532179300_ehag328-B4","first-page":"1377","article-title":"Homozygous cutaneo-tendinous forms of hypercholesteremic xanthomatosis in an exemplary familial case","volume":"118","author":"de Gennes","year":"1967","journal-title":"Bull Mem Soc Med Hop Paris"},{"key":"2026102519532179300_ehag328-B5","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(75)92193-5","article-title":"Plasma exchange in the management of homozygous familial hypercholesterolemia","volume":"1","author":"Thompson","year":"1975","journal-title":"Lancet"},{"key":"2026102519532179300_ehag328-B6","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1136\/hrt.43.6.680","article-title":"Assessment of long-term plasma exchange for familial hypercholesterolemia","volume":"43","author":"Thompson","year":"1980","journal-title":"Br Heart J"},{"key":"2026102519532179300_ehag328-B7","first-page":"406","article-title":"Double filtration plasmapheresis","volume":"26","author":"Agishi","year":"1980","journal-title":"Trans Am Soc Artif Intern Organs"},{"key":"2026102519532179300_ehag328-B8","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/S0140-6736(81)91213-7","article-title":"Application of specific extracorporeal removal of low-density lipoprotein in familial hypercholesterolemia","volume":"2","author":"Stoffel","year":"1981","journal-title":"Lancet"},{"key":"2026102519532179300_ehag328-B9","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S0022-2275(20)37936-0","article-title":"A simple specific method for precipitation of low-density lipoproteins","volume":"24","author":"Wieland","year":"1983","journal-title":"J Lipid Res"},{"key":"2026102519532179300_ehag328-B10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0021-9150(87)90089-X","article-title":"A new low-density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regenerating unit (LDL continuous apheresis)","volume":"68","author":"Mabuchi","year":"1987","journal-title":"Atherosclerosis"},{"key":"2026102519532179300_ehag328-B11","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/j.1525-1594.1993.tb00609.x","article-title":"Lipid apheresis by hemoperfusion: in vitro efficacy and ex vivo biocompatibility of a new low-density lipoprotein adsorber compatible with human whole blood","volume":"17","author":"Schmidt","year":"1993","journal-title":"Artif Organs"},{"key":"2026102519532179300_ehag328-B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0021-9150(02)00251-4","article-title":"LDL apheresis","volume":"167","author":"Thompson","year":"2003","journal-title":"Atherosclerosis"},{"key":"2026102519532179300_ehag328-B13","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1161\/01.CIR.96.5.1381","article-title":"Plasma cholesterol regulates soluble cell adhesion molecule expression in familial hypercholesterolemia","volume":"96","author":"Sampietro","year":"1997","journal-title":"Circulation"},{"key":"2026102519532179300_ehag328-B14","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/S0021-9150(01)00633-5","article-title":"C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis","volume":"158","author":"Moriarty","year":"2001","journal-title":"Atherosclerosis"},{"key":"2026102519532179300_ehag328-B15","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1093\/eurjpc\/zwac043","article-title":"Coronary microcirculatory blood flow significantly increases upon acute and chronic cholesterol lowering: evaluation by cadmium-zinc-telluride cardiac imaging stress test","volume":"29","author":"Sampietro","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2026102519532179300_ehag328-B16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.amjmed.2022.08.016","article-title":"Acute increase in ocular microcirculation blood flow upon cholesterol removal. The eyes are the window of the heart","volume":"136","author":"Sampietro","year":"2023","journal-title":"Am J Med"},{"key":"2026102519532179300_ehag328-B17","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/1744-9987.13976","article-title":"Skin microcirculation significantly increases after lipoprotein apheresis","volume":"27","author":"Sbrana","year":"2023","journal-title":"Ther Apher Dial"},{"key":"2026102519532179300_ehag328-B18","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1111\/j.1537-2995.2009.02135.x","article-title":"Aorta and coronary angiographic follow-up of children with severe hypercholesterolemia treated with low-density lipoprotein apheresis","volume":"49","author":"Stefanutti","year":"2009","journal-title":"Transfusion"},{"key":"2026102519532179300_ehag328-B19","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s11883-023-01113-2","article-title":"Lipoprotein apheresis: current recommendations for treating familial hypercholesterolemia and elevated lipoprotein(a)","volume":"25","author":"Safarova","year":"2023","journal-title":"Curr Atheroscler Rep"},{"key":"2026102519532179300_ehag328-B20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11883-021-00911-w","article-title":"LDL apheresis and lp (a) apheresis: a clinician\u2019s perspective","volume":"23","author":"Kayikcioglu","year":"2021","journal-title":"Curr Atheroscler Rep"},{"key":"2026102519532179300_ehag328-B21","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ejim.2024.03.023","article-title":"Long-term compliance of lipoprotein apheresis patients. What is health-related quality of life?","volume":"125","author":"Dal Pino","year":"2024","journal-title":"Eur J Intern Med"},{"key":"2026102519532179300_ehag328-B22","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s12020-024-04144-0","article-title":"Pediatrics cascade screening in inherited dyslipidemias: a lipoprotein apheresis center experience","volume":"88","author":"Sbrana","year":"2025","journal-title":"Endocrine"},{"key":"2026102519532179300_ehag328-B23","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.cyto.2011.08.027","article-title":"Effects on plasma inflammatory profile and on cytokine pattern in patients with severe dyslipidemia","volume":"56","author":"Stefanutti","year":"2011","journal-title":"Cytokine"},{"key":"2026102519532179300_ehag328-B24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1253\/circj.CJ-09-0706","article-title":"Inflammation in atherosclerosis: transition from theory to practice","volume":"74","author":"Libby","year":"2010","journal-title":"Circ J"},{"key":"2026102519532179300_ehag328-B25","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1152\/physrev.00024.2005","article-title":"Cytokines in atherosclerosis: pathogenic and regulatory pathways","volume":"86","author":"Tedgui","year":"2006","journal-title":"Physiol Rev"},{"key":"2026102519532179300_ehag328-B26","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.cyto.2011.04.003","article-title":"Cytokines profile in serum of homozygous familial hypercholesterolemia is changed by LDL-apheresis","volume":"55","author":"Stefanutti","year":"2011","journal-title":"Cytokine"},{"key":"2026102519532179300_ehag328-B27","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.cyto.2011.08.038","article-title":"LDL-apheresis on plasma inflammatory markers concentration in severe dyslipidemia: implication for anti-inflammatory response","volume":"56","author":"Zenti","year":"2011","journal-title":"Cytokine"},{"key":"2026102519532179300_ehag328-B28","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1042\/cs1000191","article-title":"Acute and long-term effects of low-density lipoprotein (LDL)-apheresis on oxidative damage to LDL and reducing capacity of erythrocytes in patients with severe familial hypercholesterolaemia","volume":"100","author":"Stefanutti","year":"2001","journal-title":"Clin Sci (Lond)"},{"key":"2026102519532179300_ehag328-B29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.atherosclerosis.2004.03.011","article-title":"Effects of heparin mediated extracorporeal low-density lipoprotein precipitation beyond lowering proatherogenic lipoproteins\u2014reduction of circulating proinflammatory and procoagulatory markers","volume":"175","author":"Wang","year":"2004","journal-title":"Atherosclerosis"},{"key":"2026102519532179300_ehag328-B30","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1161\/01.CIR.95.1.76","article-title":"Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans","volume":"95","author":"Tamai","year":"1997","journal-title":"Circulation"},{"key":"2026102519532179300_ehag328-B31","doi-asserted-by":"publisher","first-page":"273","DOI":"10.33549\/physiolres.930460","article-title":"Selectins and monocyte chemotactic peptide as the markers of atherosclerosis activity","volume":"53","author":"Bl\u00e1ha","year":"2004","journal-title":"Physiol Res"},{"key":"2026102519532179300_ehag328-B32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0021-9150(98)00152-X","article-title":"LPS induced cytokine production and expression of b2-integrins and CD14 by peripheral blood mononuclear cells of patients with homozygous familial hypercholesterolemia","volume":"141","author":"Rovers","year":"1998","journal-title":"Atherosclerosis"},{"key":"2026102519532179300_ehag328-B33","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0021-9150(98)00055-0","article-title":"Improvement of coronary vasodilatation capacity through single LDL apheresis","volume":"139","author":"Mellwig","year":"1998","journal-title":"Atherosclerosis"},{"key":"2026102519532179300_ehag328-B34","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/jca.20033","article-title":"LDL-apheresis improves peripheral arterial occlusive disease with an implication for anti-inflammatory effects","volume":"20","author":"Kobayashi","year":"2005","journal-title":"Clin Apher"},{"key":"2026102519532179300_ehag328-B35","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1093\/ndt\/gfn127","article-title":"Protein adsorption during LDL-apheresis: proteomic analysis","volume":"23","author":"Dihazi","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2026102519532179300_ehag328-B36","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/00001721-199909000-00004","article-title":"Does the production of nitric oxide contribute to the early improvement after a single low-density lipoprotein apheresis in patients with peripheral arterial obstructive disease?","volume":"10","author":"Kizaki","year":"1999","journal-title":"Blood Coagul Fibrinolysis"},{"key":"2026102519532179300_ehag328-B37","doi-asserted-by":"publisher","first-page":"E1440","DOI":"10.1161\/ATV.0000000000000177","article-title":"Effect of LDL-apheresis on HDL-C functionality","volume":"61","author":"Castillo","year":"2013","journal-title":"JACC Archives"},{"key":"2026102519532179300_ehag328-B38","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.atherosclerosissup.2017.05.028","article-title":"Lipoprotein apheresis downregulates IL-1\u03b1, IL-6 and TNF-\u03b1 mRNA expression in severe dyslipidaemia","volume":"30","author":"Stefanutti","year":"2017","journal-title":"Atheroscler Suppl"},{"key":"2026102519532179300_ehag328-B39","doi-asserted-by":"publisher","first-page":"4739512","DOI":"10.1155\/2016\/4739512","article-title":"Relationship between sustained reductions in plasma lipid and lipoprotein concentrations with apheresis and plasma levels and mRNA expression of PTX3 and plasma levels of hsCRP in patients with hyperLp(a)lipoproteinemia","volume":"2016","author":"Stefanutti","year":"2016","journal-title":"Mediators Inflamm"},{"key":"2026102519532179300_ehag328-B40","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1699-0463.1963.tb01808.x","article-title":"A new serum type system in man\u2014the LP system","volume":"59","author":"Berg","year":"1963","journal-title":"Acta Pathol Microbiol Scand"},{"key":"2026102519532179300_ehag328-B41","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"2026102519532179300_ehag328-B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2022.04.017","article-title":"The long journey of lipoprotein(a) from cardiovascular curiosity to therapeutic target","volume":"349","author":"Koschinsky","year":"2022","journal-title":"Atherosclerosis"},{"key":"2026102519532179300_ehag328-B43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/0021-9150(81)90103-9","article-title":"Lipoprotein Lp(a) and the risk for myocardial infarction","volume":"38","author":"Kostner","year":"1981","journal-title":"Atherosclerosis"},{"key":"2026102519532179300_ehag328-B44","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"key":"2026102519532179300_ehag328-B45","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.atherosclerosis.2023.04.012","article-title":"Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society","volume":"374","author":"Kronenberg","year":"2023","journal-title":"Atherosclerosis"},{"key":"2026102519532179300_ehag328-B46","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.atherosclerosis.2022.04.008","article-title":"Lipoprotein(a) measurement issues: are we making a mountain out of a molehill?","volume":"349","author":"Kronenberg","year":"2022","journal-title":"Atherosclerosis"},{"key":"2026102519532179300_ehag328-B47","doi-asserted-by":"publisher","first-page":"106843","DOI":"10.1016\/j.phrs.2023.106843","article-title":"Daring to dream: targeting lipoprotein(a) as a causal and risk-enhancing factor","volume":"194","author":"Koschinsky","year":"2023","journal-title":"Pharmacol Res"},{"key":"2026102519532179300_ehag328-B48","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1080\/10408363.2023.2229915","article-title":"Lipoprotein(a): a genetically determined risk factor for cardiovascular disease","volume":"60","author":"Marcovina","year":"2023","journal-title":"Crit Rev Clin Lab Sci"},{"key":"2026102519532179300_ehag328-B49","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2026102519532179300_ehag328-B50","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.atherosclerosis.2022.03.004","article-title":"Lipoprotein(a) levels from childhood to adulthood: data in nearly 3,000 children who visited a pediatric lipid clinic","volume":"349","author":"de Boer","year":"2022","journal-title":"Atherosclerosis"},{"key":"2026102519532179300_ehag328-B51","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1161\/CIRCULATIONAHA.122.060667","article-title":"Lipoprotein(a) in youth and prediction of major cardiovascular outcomes in adulthood","volume":"147","author":"Raitakari","year":"2023","journal-title":"Circulation"},{"key":"2026102519532179300_ehag328-B52","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/phar.2851","article-title":"Role of lipoprotein(a) in atherosclerotic cardiovascular disease: a review of current and emerging therapies","volume":"43","author":"Alhomoud","year":"2023","journal-title":"Pharmacotherapy"},{"key":"2026102519532179300_ehag328-B53","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1016\/j.jacc.2023.02.033","article-title":"Clinical trial design for lipoprotein(a)-lowering therapies: JACC focus seminar 2\/3","volume":"81","author":"Malick","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026102519532179300_ehag328-B54","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1056\/NEJMe2503824","article-title":"Targeting lipoprotein(a)\u2014the next frontier in cardiovascular disease","volume":"392","author":"Rader","year":"2025","journal-title":"N Engl J Med"},{"key":"2026102519532179300_ehag328-B55","author":"Schettler"},{"key":"2026102519532179300_ehag328-B56","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"2026102519532179300_ehag328-B57","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO)","year":"2024","journal-title":"J Hepatol"},{"key":"2026102519532179300_ehag328-B58","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2026102519532179300_ehag328-B59","doi-asserted-by":"publisher","first-page":"e50415","DOI":"10.2196\/50415","article-title":"Relationship between lipoprotein(a), renal function indicators, and chronic kidney disease: evidence from a large prospective cohort study","volume":"10","author":"Liu","year":"2024","journal-title":"JMIR Public Health Surveill"},{"key":"2026102519532179300_ehag328-B60","doi-asserted-by":"publisher","first-page":"105689","DOI":"10.1016\/j.phrs.2021.105689","article-title":"Beyond lipoprotein(a) plasma measurements: lipoprotein(a) and inflammation","volume":"169","author":"Reyes-Soffer","year":"2021","journal-title":"Pharmacol Res"},{"key":"2026102519532179300_ehag328-B61","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1093\/eurjpc\/zwae177","article-title":"Cardiovascular risk factors and aortic valve stenosis: towards 10-year absolute risk charts for primary prevention","volume":"32","author":"Kjeldsen","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2026102519532179300_ehag328-B62","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1093\/eurheartj\/ehae191","article-title":"Eight reasons why lipoprotein(a) should be measured in everyone at least once in a lifetime","volume":"45","author":"Arsenault","year":"2024","journal-title":"Eur Heart J"},{"key":"2026102519532179300_ehag328-B63","first-page":"408","article-title":"Triangel oder Mahler-Hammer im Konzert von kardiovaskul\u00e4ren Risikofaktoren","volume":"9","author":"Schettler","year":"2023","journal-title":"Nephrologie aktuell"},{"key":"2026102519532179300_ehag328-B64","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11789-019-00094-4","article-title":"Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels","volume":"14","author":"Schettler","year":"2019","journal-title":"Clin Res Cardiol Suppl"},{"key":"2026102519532179300_ehag328-B65","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/1744-9987.13780","article-title":"The German Lipoprotein Apheresis Registry\u2014summary of the ninth annual report","volume":"26","author":"Schettler","year":"2022","journal-title":"Ther Apher Dial"},{"key":"2026102519532179300_ehag328-B66","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.atherosclerosissup.2012.10.005","article-title":"Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern","volume":"14","author":"von Dryander","year":"2013","journal-title":"Atheroscler Suppl"},{"key":"2026102519532179300_ehag328-B67","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1161\/CIRCULATIONAHA.113.002432","article-title":"Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study","volume":"128","author":"Leebmann","year":"2013","journal-title":"Circulation"},{"key":"2026102519532179300_ehag328-B68","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/jca.21695","article-title":"Real-world study: escalating targeted lipid-lowering treatment with PCSK9-inhibitors and lipoprotein apheresis","volume":"34","author":"Spitth\u00f6ver","year":"2019","journal-title":"J Clin Apher"},{"key":"2026102519532179300_ehag328-B69","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1093\/eurheartj\/ehw388","article-title":"Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial","volume":"37","author":"Moriarty","year":"2016","journal-title":"Eur Heart J"},{"key":"2026102519532179300_ehag328-B70","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.atherosclerosissup.2012.10.017","article-title":"Lipoprotein apheresis\u2013more than just cholesterol reduction?","volume":"14","author":"Neumann","year":"2013","journal-title":"Atheroscler Suppl"},{"key":"2026102519532179300_ehag328-B71","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.atherosclerosis.2019.12.015","article-title":"Corrigendum to \u201clipoprotein apheresis efficacy, challenges and outcomes: a descriptive analysis from the UK Lipoprotein Apheresis Registry, 1989\u20132017\u201d","volume":"294","author":"Pottle","year":"2020","journal-title":"Atherosclerosis"},{"key":"2026102519532179300_ehag328-B72","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.jacl.2017.04.114","article-title":"Toward an international consensus-integrating lipoprotein apheresis and new lipid-lowering drugs","volume":"11","author":"Stefanutti","year":"2017","journal-title":"J Clin Lipidol"},{"key":"2026102519532179300_ehag328-B73","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.transci.2018.07.015","article-title":"Reduced incidence of cardiovascular events in hyper-Lp(a) patients on lipoprotein apheresis. The G.I.L.A. (Gruppo Interdisciplinare Aferesi Lipoproteica) pilot study","volume":"57","author":"Bigazzi","year":"2018","journal-title":"Transfus Apher Sci"},{"key":"2026102519532179300_ehag328-B74","doi-asserted-by":"publisher","first-page":"118601","DOI":"10.1016\/j.atherosclerosis.2024.118601","article-title":"The German Lipoprotein Apheresis Registry\u2014summary of the eleventh annual report","volume":"398","author":"Schettler","year":"2024","journal-title":"Atherosclerosis"},{"key":"2026102519532179300_ehag328-B75","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0021-9150(00)00371-3","article-title":"The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels","volume":"152","author":"Kroon","year":"2000","journal-title":"Atherosclerosis"},{"key":"2026102519532179300_ehag328-B76","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.jacl.2019.10.003","article-title":"Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: results of the randomized, controlled, open-label DE LAVAL study","volume":"13","author":"Baum","year":"2019","journal-title":"J Clin Lipidol"},{"key":"2026102519532179300_ehag328-B77","doi-asserted-by":"publisher","first-page":"103660","DOI":"10.1016\/j.transci.2023.103660","article-title":"Alirocumab in lipoprotein apheresis: a synergy for patients with high-Lp(a)","volume":"62","author":"Sbrana","year":"2023","journal-title":"Transfus Apher Sci"},{"key":"2026102519532179300_ehag328-B78","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1177\/2047487319868792","article-title":"HeFH in real life, how to: more evolocumab than authorized","volume":"27","author":"Sbrana","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"2026102519532179300_ehag328-B79","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/1744-9987.14025","article-title":"Inclisiran and lipoprotein apheresis in statin intolerance heterozygous FH patients: a case series","volume":"27","author":"Dal Pino","year":"2023","journal-title":"Ther Apher Dial"},{"key":"2026102519532179300_ehag328-B80","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S0140-6736(21)02001-8","article-title":"Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study","volume":"399","author":"Tromp","year":"2022","journal-title":"Lancet"},{"key":"2026102519532179300_ehag328-B81","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"2023 update on European Atherosclerosis Society consensus statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance","volume":"44","author":"Cuchel","year":"2023","journal-title":"Eur Heart J"},{"key":"2026102519532179300_ehag328-B82","doi-asserted-by":"publisher","first-page":"117525","DOI":"10.1016\/j.atherosclerosis.2024.117525","article-title":"Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolaemia: an expert consensus statement from ERKNet and ESPN","volume":"392","author":"Reijman","year":"2024","journal-title":"Atherosclerosis"},{"key":"2026102519532179300_ehag328-B83","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.jacl.2025.03.015","article-title":"Long-term experience with lomitapide treatment in patients with homozygous familial hypercholesterolemia: over 10 years of efficacy and safety data","volume":"19","author":"Arca","year":"2025","journal-title":"J Clin Lipidol"},{"key":"2026102519532179300_ehag328-B84","doi-asserted-by":"publisher","first-page":"e817","DOI":"10.1016\/j.jacl.2024.05.006","article-title":"Real-world experience of long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia treated and untreated with lipoprotein apheresis","volume":"18","author":"Stefanutti","year":"2024","journal-title":"J Clin Lipidol"},{"key":"2026102519532179300_ehag328-B85","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1177\/2047487319864191","article-title":"Null receptor homozygous familial hypercholesterolaemia: quoad valetudinem long life treatment","volume":"27","author":"Sampietro","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"2026102519532179300_ehag328-B86","doi-asserted-by":"publisher","first-page":"119187","DOI":"10.1016\/j.atherosclerosis.2025.119187","article-title":"Real-world family planning and pregnancy practices in women with homozygous familial hypercholesterolemia","volume":"404","author":"Mulder","year":"2025","journal-title":"Atherosclerosis"},{"key":"2026102519532179300_ehag328-B87","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.3390\/nu16172927","article-title":"Characteristics, physiopathology and management of dyslipidemias in pregnancy. A narrative review","volume":"16","author":"Formisano","year":"2024","journal-title":"Nutrients"},{"key":"2026102519532179300_ehag328-B88","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s12020-024-03941-x","article-title":"Women and lipoprotein apheresis: another side of gender medicine","volume":"86","author":"Dal Pino","year":"2024","journal-title":"Endocrine"},{"key":"2026102519532179300_ehag328-B89","doi-asserted-by":"publisher","first-page":"104062","DOI":"10.1016\/j.transci.2024.104062","article-title":"Management of a young HoFH patient during pregnancy using lipoprotein apheresis (whole blood): a novel experience","volume":"64","author":"Stefanutti","year":"2025","journal-title":"Transfus Apher Sci"},{"key":"2026102519532179300_ehag328-B90","doi-asserted-by":"publisher","first-page":"e304","DOI":"10.1161\/ATV.0000000000000177","article-title":"Lipoprotein apheresis: utility, outcomes, and implementation in clinical practice: a scientific statement from the American Heart Association","volume":"44","author":"Gianos","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026102519532179300_ehag328-B91","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12887-022-03192-7","article-title":"Vascular access for lipid apheresis: a challenge in young children with homozygous familial hypercholesterolemia","volume":"22","author":"Lischka","year":"2022","journal-title":"BMC Pediatr"},{"key":"2026102519532179300_ehag328-B92","doi-asserted-by":"publisher","first-page":"103205","DOI":"10.1016\/j.transci.2021.103205","article-title":"Apheresis at the National Institutes of Health: a unique nursing experience","volume":"60","author":"Ravi","year":"2021","journal-title":"Transfus Apher Sci"},{"key":"2026102519532179300_ehag328-B93","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1177\/1129729820908090","article-title":"Vascular access in lipoprotein apheresis: save the vein save the life","volume":"22","author":"Pianelli","year":"2021","journal-title":"J Vasc Access"},{"key":"2026102519532179300_ehag328-B94","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s00467-018-3906-6","article-title":"Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia-target attainment requires further increase of intensity","volume":"33","author":"Klaus","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"2026102519532179300_ehag328-B95","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/00002216-198907000-00057","article-title":"Improvement of peripheral circulation by low density lipoprotein adsorption","volume":"35","author":"Agishi","year":"1989","journal-title":"ASAIO Trans"},{"key":"2026102519532179300_ehag328-B96","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.5551\/jat.64639","article-title":"Lipoprotein apheresis alleviates treatment-resistant peripheral artery disease despite the normal range of atherogenic lipoproteins: the LETS-PAD study","volume":"31","author":"Ueda","year":"2024","journal-title":"J Atheroscler Thromb"},{"key":"2026102519532179300_ehag328-B97","doi-asserted-by":"publisher","first-page":"679","DOI":"10.5551\/jat.RV17033","article-title":"Familial hypercholesterolemia and lipoprotein apheresis","volume":"26","author":"Makino","year":"2019","journal-title":"J Atheroscler Thromb"},{"key":"2026102519532179300_ehag328-B98","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1093\/ndt\/gfp342","article-title":"Low-density lipoprotein apheresis for haemodialysis patients with peripheral arterial disease reduces reactive oxygen species production via suppression of NADPH oxidase gene expression in leucocytes","volume":"24","author":"Hara","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"2026102519532179300_ehag328-B99","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.5551\/jat.ED269","article-title":"Treating PAD patients with lipoprotein apheresis","volume":"31","author":"Harada-Shiba","year":"2024","journal-title":"J Atheroscler Thromb"},{"key":"2026102519532179300_ehag328-B100","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1253\/circj.CJ-24-0830","article-title":"Efficacy of Rheocarna\u00ae, a novel apheresis device, in patients with No- or poor-option chronic limb-threatening ischemia","volume":"89","author":"Soga","year":"2025","journal-title":"Circ J"},{"key":"2026102519532179300_ehag328-B101","doi-asserted-by":"publisher","first-page":"v59","DOI":"10.1093\/ndt\/gfg1050","article-title":"LDL-apheresis and immunoadsorption: novel methods in the treatment of renal diseases refractory to conventional therapy","volume":"18","author":"Su\u0142owicz","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"2026102519532179300_ehag328-B102","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/S0140-6736(82)91513-6","article-title":"Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease","volume":"2","author":"Moorhead","year":"1982","journal-title":"Lancet"},{"key":"2026102519532179300_ehag328-B103","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1111\/j.1525-1594.1996.tb04571.x","article-title":"Development of selective low-density lipoprotein (LDL) apheresis system: immobilized polyanion as LDL-specific adsorption for LDL apheresis system","volume":"20","author":"Tani","year":"1996","journal-title":"Artif Organs"},{"key":"2026102519532179300_ehag328-B104","first-page":"1153","article-title":"Possible therapeutic application of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS)","volume":"30","author":"Tojo","year":"1988","journal-title":"Nihon Jinzo Gakkai Shi"},{"key":"2026102519532179300_ehag328-B105","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2147\/IJNRD.S248610","article-title":"Low-density lipoprotein apheresis in patients with acute kidney injury due to minimal change disease requiring acute renal replacement therapy","volume":"13","author":"Terada","year":"2020","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"2026102519532179300_ehag328-B106","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s10157-013-0930-5","article-title":"Beneficial effect of LDL-apheresis in refractory nephrotic syndrome","volume":"18","author":"Muso","year":"2014","journal-title":"Clin Exp Nephrol"},{"key":"2026102519532179300_ehag328-B107","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1159\/000046112","article-title":"Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL apheresis compared with steroid monotherapy","volume":"89","author":"Muso","year":"2001","journal-title":"Nephron"},{"key":"2026102519532179300_ehag328-B108","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s10157-014-0996-8","article-title":"Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS study","volume":"19","author":"Muso","year":"2015","journal-title":"Clin Exp Nephrol"},{"key":"2026102519532179300_ehag328-B109","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1159\/000437338","article-title":"A prospective observational survey on the long-term effect of LDL apheresis on drug-resistant nephrotic syndrome","volume":"5","author":"Muso","year":"2015","journal-title":"Nephron Extra"},{"key":"2026102519532179300_ehag328-B110","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/1744-9987.13694","article-title":"Favorable therapeutic efficacy of low-density lipoprotein apheresis for nephrotic syndrome with impaired renal function","volume":"26","author":"Muso","year":"2022","journal-title":"Ther Apher Dial"},{"key":"2026102519532179300_ehag328-B111","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/1744-9987.13749","article-title":"The Japanese Society for Apheresis clinical practice guideline for therapeutic apheresis","volume":"25","author":"Abe","year":"2021","journal-title":"Ther Apher Dial"},{"key":"2026102519532179300_ehag328-B112","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/jca.22043","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice","volume":"38","author":"Connelly-Smith","year":"2023","journal-title":"J Clin Apher"},{"key":"2026102519532179300_ehag328-B113","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3390\/vision7040072","article-title":"Non-arteritic anterior ischemic optic neuropathy (NA-AION): a comprehensive overview","volume":"7","author":"Salvetat","year":"2023","journal-title":"Vision"},{"key":"2026102519532179300_ehag328-B114","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.molmed.2016.06.009","article-title":"A revised hemodynamic theory of age-related macular degeneration","volume":"22","author":"Gelfand","year":"2016","journal-title":"Trends Mol Med"},{"key":"2026102519532179300_ehag328-B115","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1159\/000094574","article-title":"Is the efficacy of LDL apheresis in ischemic optic neuropathy linked to a reduction in endothelial activation markers?","volume":"24","author":"Ramunni","year":"2006","journal-title":"Blood Purif"},{"key":"2026102519532179300_ehag328-B116","first-page":"221","article-title":"Preliminary analysis of the final multicenter investigation of rheopheresis for age related macular degeneration (AMD) trial (MIRA-1) results","volume":"104","author":"Pulido","year":"2006","journal-title":"Trans Am Ophthalmol Soc"},{"key":"2026102519532179300_ehag328-B117","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s00417-009-1113-7","article-title":"Prospective, randomized, controlled clinical study evaluating the efficacy of Rheopheresis for dry age-related macular degeneration. Dry AMD treatment with Rheopheresis Trial-ART","volume":"247","author":"Koss","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2026102519532179300_ehag328-B118","doi-asserted-by":"publisher","first-page":"8","DOI":"10.31348\/2023\/2","article-title":"Rheopheresis in the treatment of age-related macular degeneration","volume":"79","author":"Langrov\u00e1","year":"2022","journal-title":"Cesk Slov Oftalmol"},{"key":"2026102519532179300_ehag328-B119","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.atherosclerosissup.2012.10.018","article-title":"Acute and chronic effects of therapeutic apheresis","volume":"14","author":"Ramunni","year":"2013","journal-title":"Atheroscler Suppl"},{"key":"2026102519532179300_ehag328-B120","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1177\/0194599819859885","article-title":"Clinical practice guideline: sudden hearing loss (update)","volume":"161","author":"Chandrasekhar","year":"2019","journal-title":"Otolaryngol Head Neck Surg"},{"key":"2026102519532179300_ehag328-B121","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/S0140-6736(02)11768-5","article-title":"Fibrinogen and LDL apheresis in treatment of sudden hearing loss: a randomised multicentre trial","volume":"360","author":"Suckf\u00fcll","year":"2002","journal-title":"Lancet"},{"key":"2026102519532179300_ehag328-B122","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.clinthera.2024.12.016","article-title":"Efficacy of apheresis in the remission of sudden sensorineural hearing loss: a systematic review and meta-analysis","volume":"47","author":"Moreno-Herraiz","year":"2025","journal-title":"Clin Ther"},{"key":"2026102519532179300_ehag328-B123","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.3390\/jcm14124134","article-title":"Exploring the impact of first trimester elevated lipoprotein(a) levels on preeclampsia, preterm delivery, and fetal growth restriction","volume":"14","author":"Galani","year":"2025","journal-title":"J Clin Med"},{"key":"2026102519532179300_ehag328-B124","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/01.AOG.0000152351.13671.99","article-title":"Diagnosis, prevention, and management of eclampsia","volume":"105","author":"Sibai","year":"2005","journal-title":"Obstet Gynecol"},{"key":"2026102519532179300_ehag328-B125","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Emerging Risk Factors Collaboration","year":"2009","journal-title":"JAMA"},{"key":"2026102519532179300_ehag328-B126","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/01443615.2019.1603214","article-title":"Correlation of elevated levels of lipoprotein(a), high-density lipoprotein and low-density lipoprotein with severity of preeclampsia: a prospective longitudinal study","volume":"40","author":"Konrad","year":"2020","journal-title":"J Obstet Gynaecol"},{"key":"2026102519532179300_ehag328-B127","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/jmf.14.2.91.95","article-title":"Changes of plasma lipoprotein(a) during and after normal pregnancy in Caucasians","volume":"14","author":"Manten","year":"2003","journal-title":"J Matern Fetal Neonatal Med"},{"key":"2026102519532179300_ehag328-B128","doi-asserted-by":"publisher","first-page":"1190446","DOI":"10.3389\/fmed.2023.1190446","article-title":"Case report: lipoprotein apheresis reduces the risk of cardiovascular events and prolongs pregnancy in a woman with severely elevated lipoprotein(a), cardiovascular disease, and a high risk of preeclampsia","volume":"10","author":"Marl\u0229ga-Linert","year":"2023","journal-title":"Front Med"},{"key":"2026102519532179300_ehag328-B129","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/MOL.0000000000000939","article-title":"Pancreatic and cardiometabolic complications of severe hypertriglyceridaemia","volume":"35","author":"Bashir","year":"2024","journal-title":"Curr Opin Lipidol"},{"key":"2026102519532179300_ehag328-B130","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.atherosclerosissup.2012.10.020","article-title":"A three-month-old infant with severe hyperchylomicronemia: molecular diagnosis and extracorporeal treatment","volume":"14","author":"Stefanutti","year":"2013","journal-title":"Atheroscler Suppl"},{"key":"2026102519532179300_ehag328-B131","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.atherosclerosissup.2019.08.032","article-title":"A successful term pregnancy with severe hypertriglyceridaemia and acute pancreatitis. Clinical management and review of the literature","volume":"40","author":"Bashir","year":"2019","journal-title":"Atheroscler Suppl"},{"key":"2026102519532179300_ehag328-B132","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.atherosclerosissup.2015.02.017","article-title":"Treatment of primary hypertriglyceridemia states\u2014general approach and the role of extracorporeal methods","volume":"18","author":"Stefanutti","year":"2015","journal-title":"Atheroscler Suppl"},{"key":"2026102519532179300_ehag328-B133","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s11883-023-01140-z","article-title":"Updates in drug treatment of severe hypertriglyceridemia","volume":"25","author":"Gouni-Berthold","year":"2023","journal-title":"Curr Atheroscler Rep"},{"key":"2026102519532179300_ehag328-B134","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1056\/NEJMc2306575","article-title":"Volanesorsen to prevent acute pancreatitis in hypertriglyceridemia","volume":"390","author":"Alexander","year":"2024","journal-title":"N Engl J Med"},{"key":"2026102519532179300_ehag328-B135","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41591-023-02222-w","article-title":"Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial","volume":"29","author":"Rosenson","year":"2023","journal-title":"Nat Med"},{"key":"2026102519532179300_ehag328-B136","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/j.1525-1594.2009.00810.x","article-title":"Therapeutic plasma exchange in patients with severe hypertriglyceridemia: a multicenter study","volume":"33","author":"Stefanutti","year":"2009","journal-title":"Artif Organs"},{"key":"2026102519532179300_ehag328-B137","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jacc.2020.05.070","article-title":"Targeting RNA with antisense oligonucleotides and small interfering RNA. JACC state-of-the-art review","volume":"76","author":"Katzmann","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026102519532179300_ehag328-B138","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1080\/13543784.2016.1254187","article-title":"Lomitapide for the treatment of hypertriglyceridemia","volume":"25","author":"Brahm","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"2026102519532179300_ehag328-B139","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.hlc.2020.09.943","article-title":"Integrated guidance for enhancing the care of familial hypercholesterolaemia in Australia","volume":"30","author":"Watts","year":"2021","journal-title":"Heart Lung Circ"},{"key":"2026102519532179300_ehag328-B140","doi-asserted-by":"publisher","first-page":"641","DOI":"10.5551\/jat.GL2022","article-title":"Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2022","volume":"31","author":"Okamura","year":"2024","journal-title":"J Atheroscler Thromb"},{"key":"2026102519532179300_ehag328-B141","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice","volume":"18","author":"Koschinsky","year":"2024","journal-title":"J Clin Lipidol"},{"key":"2026102519532179300_ehag328-B142","first-page":"355","article-title":"Lipid apheresis after heart transplantation\u2014the Dresden experience","volume":"22","author":"Julius","year":"2010","journal-title":"Transplantationsmedizin"},{"key":"2026102519532179300_ehag328-B143","doi-asserted-by":"publisher","first-page":"1007636","DOI":"10.3389\/fcvm.2022.1007636","article-title":"The potential of heparin-induced extracorporeal LDL\/fibrinogen precipitation (H.E.L.P.)-apheresis for patients with severe acute or chronic COVID-19","volume":"9","author":"Jaeger","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2026102519532179300_ehag328-B144","doi-asserted-by":"publisher","first-page":"e22094","DOI":"10.1002\/jca.22094","article-title":"Comorbidity in lipoprotein apheresis: their role in the era of new lipid-lowering therapies","volume":"39","author":"Sbrana","year":"2024","journal-title":"J Clin Apher"},{"key":"2026102519532179300_ehag328-B145","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1093\/eurjpc\/zwae054","article-title":"Lipoprotein apheresis reduces major adverse cardiovascular event incidence in high-lipoprotein (a) subjects on proprotein convertase subtilisin\/kexin type 9 inhibitor therapy","volume":"31","author":"Sbrana","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2026102519532179300_ehag328-B146","doi-asserted-by":"publisher","first-page":"e22132","DOI":"10.1002\/jca.22132","article-title":"Effects of rheopheresis in dialysis patients with peripheral artery disease and diabetic foot ulcers: a multicentric Italian study","volume":"39","author":"Altobelli","year":"2024","journal-title":"J Clin Apher"},{"key":"2026102519532179300_ehag328-B147","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2327-5790.1000113","article-title":"Lipoprotein glomerulopathy: molecular characterization of three Italian patients and literature survey","volume":"3","author":"Bertolini","year":"2014","journal-title":"J Genet Disor Genet Rep"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/40\/5959\/68340893\/ehag328.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/40\/5959\/68340893\/ehag328.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T23:53:31Z","timestamp":1792972411000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/47\/40\/5959\/8687706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":147,"journal-issue":{"issue":"40","published-online":{"date-parts":[[2026,5,19]]},"published-print":{"date-parts":[[2026,10,26]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehag328","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,21]]},"published":{"date-parts":[[2026,5,19]]}}}